Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing-remitting course of disease and after clinical isolated syndrome

被引:27
作者
Sladkova, Vladimira [1 ]
Mares, Jan [1 ]
Lubenova, Blanka [1 ]
Zapletalova, Jana [1 ]
Stejskal, David [1 ]
Hlustik, Petr [1 ]
Kanovsky, Petr [1 ]
机构
[1] Univ Hosp Olomouc, Dept Neurol, Olomouc, Czech Republic
关键词
Multiple sclerosis; CIS; RRMS; CSF; Inflammatory markers; Degenerative markers; TAU-PROTEIN; AXONAL DAMAGE; CYSTATIN-C; SUBGROUPS;
D O I
10.1179/016164110X12816242542535
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Literature includes evidence of initial predominance of inflammation and later development of neurodegeneration in the pathogenesis of multiple sclerosis (MS). Objective: To search for differences in inflammatory and degenerative cerebrospinal fluid (CSF) markers between relapsing-remitting MS (RRMS) and the clinical isolated syndrome (CIS). Methods: A total of 148 subjects were evaluated, 65 MS patients (45 RRMS and 20 CIS) and 83 controls. The evaluated parameters included albumin quotient and prealbumin, transferrin, C3 and C4 complement factors, haptoglobin, beta-2-microglobulin, orosomucoid, alpha-1-antitrypsin, apolipoprotein A-I, apolipoprotein B, cystatin C, neuron-specific enolase, tau protein, beta-amyloid, oligoclonal IgG band (OCB), and IgG quotient (QIgG). Results: No differences were found in the inflammatory and degenerative CSF markers between patients with RRMS and CIS. QIgG was higher in RRMS than that in CIS but the number of OCB was higher after CIS. Cystatin C levels were significantly lower in RRMS compared to the other groups. It can be considered an indicator of the demyelination degree. Normal values of beta-amyloid were less frequent in RRMS compared to those in controls.
引用
收藏
页码:415 / 420
页数:6
相关论文
共 50 条
  • [41] MIF in the cerebrospinal fluid is decreased during relapsing-remitting while increased in secondary progressive multiple sclerosis
    Hjaeresen, Simone
    Sejbaek, Tobias
    Axelsson, Markus
    Mortensen, Sif Klovedal
    Vinslov-Jensen, Helle
    Pihl-Jensen, Gorm
    Novakova, Lenka
    Pedersen, Christian Bonde
    Halle, Bo
    Poulsen, Frantz Rom
    Zhang, Mengliang
    Benedikz, Eirikur
    Frederiksen, Jette Lautrup
    Lycke, Jan
    Illes, Zsolt
    Fex-Svenningsen, Asa
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2022, 439
  • [42] Clinical features of relapsing-remitting multiple sclerosis prognostic factors
    Fernández-Fernández, O
    REVISTA DE NEUROLOGIA, 2002, 35 (11) : 1067 - 1073
  • [43] Cerebrovascular reactivity and disease activity in relapsing-remitting multiple sclerosis
    Smolinski, Lukasz
    Litwin, Tomasz
    Kruk, Karolina
    Skowronska, Marta
    Kurkowska-Jastrzebska, Iwona
    Czlonkowska, Anna
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 29 (02): : 183 - 188
  • [44] Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis
    A. Melin
    O. Outteryck
    N. Collongues
    H. Zéphir
    M. C. Fleury
    F. Blanc
    A. Lacour
    J. C. Ongagna
    A. S. Berteloot
    P. Vermersch
    J. de Sèze
    Journal of Neurology, 2012, 259 : 1215 - 1221
  • [45] Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis
    Melin, A.
    Outteryck, O.
    Collongues, N.
    Zephir, H.
    Fleury, M. C.
    Blanc, F.
    Lacour, A.
    Ongagna, J. C.
    Berteloot, A. S.
    Vermersch, P.
    de Seze, J.
    JOURNAL OF NEUROLOGY, 2012, 259 (06) : 1215 - 1221
  • [46] Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis
    Rodriguez de Castro, Belen
    Martinez-Mugica Barbosa, Cristina
    Ayastuy Ruiz, Aitor
    Fernandez Gonzalez, Beatriz
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2021, 28 (02) : 112 - 114
  • [47] Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis
    Pasca, Matteo
    Forci, Benedetta
    Mariottini, Alice
    Mechi, Claudia
    Barilaro, Alessandro
    Massacesi, Luca
    Repice, Anna Maria
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 47
  • [48] Facial emotion recognition in patients with relapsing-remitting multiple sclerosis
    Fereydouni, Soodabe
    Hadianfard, Habib
    Ashjazadeh, Nahid
    NEUROLOGY ASIA, 2019, 24 (04) : 327 - 332
  • [49] Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis
    Cocco, E.
    Marchi, P.
    Sardu, C.
    Russo, P.
    Paolillo, A.
    Mascia, M. G.
    Solla, M.
    Frau, J.
    Lorefice, L.
    Massole, S.
    Floris, G.
    Marrosu, M. G.
    MULTIPLE SCLEROSIS JOURNAL, 2007, 13 (08) : 975 - 980
  • [50] Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis
    Arnal-Garcia, Carmen
    Rosa Garcia-Montero, Ma
    Malaga, Ignacio
    Millan-Pascual, Jorge
    Oliva-Nacarino, Pedro
    Ramio-Torrenta, Lluis
    Oreja-Guevara, Celia
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2013, 17 (01) : 50 - 54